Integrin signaling represents a promising but emerging therapeutic target for Parkinson's disease (PD). While no companies have advanced integrin-specific therapies into clinical trials for PD specifically, several companies have programs targeting related pathways including focal adhesion kinase (FAK), integrin-linked kinase (ILK), and cell adhesion mechanisms that intersect with neurodegenerative processes. This page catalogs companies working on integrin-related approaches and relevant research.
<div class="infobox">
<div class="infobox-header">Integrin Pathway PD Therapy Landscape</div>
<div class="infobox-content">
<table>
<tr><th>Direct Integrin Agonists</th><td>Research only</td></tr>
<tr><th>FAK Modulators</th><td>Preclinical</td></tr>
<tr><th>ILK Inhibitors</th><td>Research only</td></tr>
<tr><th>Cell Adhesion Therapies</th><td>Preclinical</td></tr>
</table>
</div>
</div>
Several major pharmaceutical companies with PD programs work on pathways that intersect with integrin signaling, particularly LRRK2 (leucine-rich repeat kinase 2) which regulates integrin-dependent signaling [1].
Headquarters: South San Francisco, California, USA Ticker: NASDAQ: DNLI Focus: Biopharmaceuticals for neurodegenerative diseases
Denali Therapeutics is leading the development of LRRK2 inhibitors for Parkinson's disease. While not targeting integrins directly, LRRK2 signaling intersects with integrin pathways through multiple mechanisms:
Pipeline:
| Drug | Mechanism | Phase | Status |
|------|-----------|-------|--------|
| DNL151 (BIIB122) | LRRK2 inhibitor | Phase 1b | Completed |
| DNL343 | LRRK2 inhibitor | Phase 1 | Active |
Headquarters: Cambridge, Massachusetts, USA Ticker: NASDAQ: BIIB Focus: Neurodegenerative disease therapies
Biogen has an active Parkinson's disease pipeline through its partnership with Denali Therapeutics on LRRK2 inhibitors:
Headquarters: Basel, Switzerland Ticker: SIX: RO Focus: Neuroscience
Roche has an active neuroscience division with PD programs:
Several companies provide research tools and platform technologies relevant to integrin drug discovery:
| Company | Technology | Relevance |
|---------|-----------|-----------|
| ChemieTek | Small molecule libraries | FAK inhibitor screening compounds |
| MedChemExpress | Research chemicals | Integrin ligand mimetics |
| Tocris/Bio-Techne | Biological reagents | Integrin research tools |
| R&D Systems | Proteins | Integrin subunit research |
The integrin-PD field remains primarily academic, with most advances coming from research institutions:
Integrin-targeting drugs are approved for other conditions, demonstrating clinical viability [3](https://pubmed.ncbi.nlm.nih.gov/32990156/):
| Drug | Target | Indication | Company | Status |
|------|--------|-----------|--------|--------|
| Natalizumab | α4 integrin | Multiple sclerosis | Biogen/Elan | Approved |
| Abciximab | αIIbβ3 | Anti-platelet | Eli Lilly | Approved |
| Vedolizumab | α4β7 | IBD | Takeda | Approved |
| Lifitegrast | LFA-1 | Dry eye | Novartis | Approved |
These precedents demonstrate that integrin modulation is clinically feasible. Repurposing or analog development for CNS indications remains an opportunity.
Focal adhesion kinase (FAK) is a central mediator of integrin signaling. FAK modulators in development include:
Rather thanBlocking integrins, activating integrins may support neuronal survival:
Microglial integrins drive neuroinflammation in PD. Targeting these may reduce pathology [5](https://doi.org/10.1002/glia.23945):
Several companies have platforms that could be applied to integrin-PD therapies:
Focus: Phenotypic screening and computational biology
Recursion uses phenotypic screening to identify therapeutic candidates across multiple disease areas including neurodegeneration. Their approach could identify integrin modulators through unbiased phenotypic screening.
Focus: Neurodegeneration
Vincere Biosciences focuses on molecular targets in neurodegeneration with an emphasis on protein homeostasis and cell stress pathways. Integrin-dependent cell adhesion may be relevant to their platform.
Focus: Protein engineering
Manifold Bio's protein engineering capabilities could be applied to developing integrin-targeting therapeutic antibodies or engineered proteins.
The following diagram shows the key molecular relationships involving PD Integrin Signaling Therapy Companies discovered through SciDEX knowledge graph analysis: